C tissue of lungs for the duration of the progression of the disease [9]. However, to date, there is no report around the development of a product that could act inside a multifactorial way for the management of pulmonary fibrosis. We present a holistic approach on the use of pulmonary surfactants to create nanosized liposomes encapsulating antioxidant phytochemicals, naringin that exhibits multi-pathway interference within the approach of inflammation. Considering the chronic disease, we opted to get a non-invasive and patient-friendly aerosol program that would enable to improve compliance to therapy. The aerosol inhalation of your liposomal naringin achieved optimal formulation parameters like higher entrapment efficiency, size, zeta possible airway patency, and in vitro lung deposition. Therapeutic outcomes inside the bleomycin-induced lung fibrosis animal model recommended the effectiveness with the liposomal naringin by the inhalation route. As a result, the easy-to-scale up formulation of liposomal naringin utilizing pulmonary surfactants provides a potential platform for aerosol delivery, thereby expanding the clinical application within the treatment of pulmonary fibrosis inside the future. The present formulation presents a versatile technology that may be optimized to incorporate a number of hydrophobic drugs that should allow efficient localized delivery in the therapeutic agents in the management of several lungs diseases like acute respiratory distress syndrome, acute lung injury, lung cancer, and chronic obstructive pulmonary illness.Supplementary Supplies: The following are obtainable on-line at https://www.mdpi.com/article/10 .3390/pharmaceutics13111851/s1, Figure S1: Representative histopathology pictures of essential organs from the treated group quantity IV. 5-Pentadecylresorcinol In Vivo Author Contributions: Conceptualization, S.K., H.M.A. and S.M.B.-E.; Information Curation, S.K., H.M.A., S.M.B.-E. and L.S.B.; Formal Analysis, S.K., R.B.B., N.S., A.B.N. and C.R.; Investigation, S.K., H.M.A., S.M.B.-E., L.S.B., R.B.B., N.S., A.B.N. and C.R.; Methodology, S.K., H.M.A., S.M.B.-E., L.S.B., R.B.B., N.S., A.B.N. and C.R.; Writing–Original Draft Preparation, N.S., A.B.N. and C.R.; Writing–Review and Editing, S.K., H.M.A., S.M.B.-E., L.S.B. and R.B.B. All authors have read and agreed to the published version of your manuscript. Funding: The authors extend their appreciation towards the Deputyship for Investigation Innovation, Ministry of Education in Saudi W-19-d4 Formula Arabia for funding this research function by way of the project number IFPRC-123-249-2020 and King Abdulaziz University, DSR, Jeddah, Saudi Arabia. Institutional Review Board Statement: The study was approved by the Institutional Animal Ethics Committee (IAEC) of Vidya Siri College of Pharmacy, Bangalore, India, with approval quantity: VSCP/EC/2808/2020/1 and date of approval 15 February 2021. Informed Consent Statement: Not applicable. Data Availability Statement: All of the relevant data is integrated within the manuscript. Conflicts of Interest: The authors declare no conflict of interest.
Academic Editors: Franca Ferrari, Maria Cristina Bonferon, C ar Viseras and Carmen Ferrero Received: 27 September 2021 Accepted: six November 2021 Published: 16 NovemberPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.Copyright: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is definitely an open access short article distributed beneath the terms and conditions from the Creative Commons Attribution (CC BY) license (https:// creativecommons.
